Literature DB >> 8962143

The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.

M Carroll1, M H Tomasson, G F Barker, T R Golub, D G Gilliland.   

Abstract

The TEL/PDGF beta R fusion protein is the product of the t(5;12) translocation in patients with chronic myelomonocytic leukemia. The TEL/PDGF beta R is an unusual fusion of a putative transcription factor, TEL, to a receptor tyrosine kinase. The translocation fuses the amino terminus of TEL, containing the helix-loop-helix (HLH) domain, to the transmembrane and cytoplasmic domain of the PDGF beta R. We hypothesized that TEL/PDGF beta R self-association, mediated by the HLH domain of TEL, would lead to constitutive activation of the PDGF beta R tyrosine kinase domain and cellular transformation. Analysis of in vitro-translated TEL/ PDGF beta R confirmed that the protein self-associated and that self-association was abrogated by deletion of 51 aa within the TEL HLH domain. In vivo, TEL/PDGF beta R was detected as a 100-kDa protein that was constitutively phosphorylated on tyrosine and transformed the murine hematopoietic cell line Ba/F3 to interleukin 3 growth factor independence. Transformation of Ba/F3 cells required the HLH domain of TEL and the kinase activity of the PDGF beta R portion of the fusion protein. Immunoblotting demonstrated that TEL/PDGF beta R associated with multiple signaling molecules known to associate with the activated PDGF beta R, including phospholipase C gamma 1, SHP2, and phosphoinositol-3-kinase. TEL/PDGF beta R is a novel transforming protein that self-associates and activates PDGF beta R-dependent signaling pathways. Oligomerization of TEL/PDGF beta R that is dependent on the TEL HLH domain provides further evidence that the HLH domain, highly conserved among ETS family members, is a self-association motif.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8962143      PMCID: PMC26224          DOI: 10.1073/pnas.93.25.14845

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  27 in total

1.  Ligand-independent activation of the platelet-derived growth factor beta receptor: requirements for bovine papillomavirus E5-induced mitogenic signaling.

Authors:  D Drummond-Barbosa; R R Vaillancourt; A Kazlauskas; D DiMaio
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

Review 2.  The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners.

Authors:  P Crepieux; J Coll; D Stehelin
Journal:  Crit Rev Oncog       Date:  1994

3.  The novel activation of ABL by fusion to an ets-related gene, TEL.

Authors:  P Papadopoulos; S A Ridge; C A Boucher; C Stocking; L M Wiedemann
Journal:  Cancer Res       Date:  1995-01-01       Impact factor: 12.701

4.  Molecular cloning of gene sequences regulated by platelet-derived growth factor.

Authors:  B H Cochran; A C Reffel; C D Stiles
Journal:  Cell       Date:  1983-07       Impact factor: 41.582

5.  Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.

Authors:  T R Golub; A Goga; G F Barker; D E Afar; J McLaughlin; S K Bohlander; J D Rowley; O N Witte; D G Gilliland
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

6.  Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Authors:  E Buchdunger; J Zimmermann; H Mett; T Meyer; M Müller; U Regenass; N B Lydon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.

Authors:  T R Golub; G F Barker; S K Bohlander; S W Hiebert; D C Ward; P Bray-Ward; E Morgan; S C Raimondi; J D Rowley; D G Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

8.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Authors:  E Buchdunger; J Zimmermann; H Mett; T Meyer; M Müller; B J Druker; N B Lydon
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

9.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.

Authors:  S A Shurtleff; A Buijs; F G Behm; J E Rubnitz; S C Raimondi; M L Hancock; G C Chan; C H Pui; G Grosveld; J R Downing
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

10.  Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus.

Authors:  M D Waterfield; G T Scrace; N Whittle; P Stroobant; A Johnsson; A Wasteson; B Westermark; C H Heldin; J S Huang; T F Deuel
Journal:  Nature       Date:  1983 Jul 7-13       Impact factor: 49.962

View more
  52 in total

1.  Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein.

Authors:  R Fenrick; J M Amann; B Lutterbach; L Wang; J J Westendorf; J R Downing; S W Hiebert
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

2.  Signaling in leukemia: which messenger to kill?

Authors:  W S Pear
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

3.  Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression.

Authors:  C A Kim; M L Phillips; W Kim; M Gingery; H H Tran; M A Robinson; S Faham; J U Bowie
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

4.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

5.  The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity.

Authors:  A Buijs; L van Rompaey; A C Molijn; J N Davis; A C Vertegaal; M D Potter; C Adams; S van Baal; E C Zwarthoff; M F Roussel; G C Grosveld
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

6.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

7.  Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL.

Authors:  L C Wang; F Kuo; Y Fujiwara; D G Gilliland; T R Golub; S H Orkin
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

8.  ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.

Authors:  Carmen P Montano-Almendras; Ahmed Essaghir; Hélène Schoemans; Inci Varis; Laura A Noël; Amélie I Velghe; Dominique Latinne; Laurent Knoops; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

9.  Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

Authors:  Elizabeth H Stover; Jing Chen; Cedric Folens; Benjamin H Lee; Nicole Mentens; Peter Marynen; Ifor R Williams; D Gary Gilliland; Jan Cools
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-11       Impact factor: 11.205

10.  Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Authors:  Manabu Kurokawa; Takahiro Ito; Chih-Sheng Yang; Chen Zhao; Andrew N Macintyre; David A Rizzieri; Jeffrey C Rathmell; Michael W Deininger; Tannishtha Reya; Sally Kornbluth
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.